- Fovia Ai
MONROE TOWNSHIP, N.J., Nov. 26, 2017 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced today key achievements that further position the company to afford patients and physicians greater choice when it comes to their imaging needs. The announcement sets the stage for the company's presence at the Radiological Society of North America (RSNA) Annual Meeting (South Hall A Booth# 1911), which will highlight the breadth, depth and ongoing advancement of its diagnostic imaging solutions and services portfolio.
"We've remained relentless in our pursuit to consistently deliver diagnostic imaging solutions and services that focus on efficacy, safety, quality and cost effectiveness and are aligned with the distinct needs of patients and physicians," said Fulvio Renoldi Bracco, Chief Executive Officer at Bracco Imaging. "These milestones, as well as our successful track record of bringing innovative products and solutions to the diagnostic imaging market, demonstrate our unwavering dedication to this end."
The following is a review of the Bracco Diagnostics Inc. major achievements for 2017:
Alberto Spinazzi, MD, Senior Vice President, Head of Global Medical and Regulatory Affairs, Bracco Group added, "These achievements affirm our continued commitment to help healthcare professionals provide optimal and high quality patient care. Besides, we are proud to work collaboratively with the U.S. FDA and many institutions across the country, to improve the safe and effective use of our imaging agents."
About Bracco Imaging
Bracco Imaging S.p.A., part of the Bracco Group, is one of the world's leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions that meet medical needs.
Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers. The diagnostic imaging portfolio is completed by a range of medical devices and advanced administration systems for contrast imaging products.
The Company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. With on-going research covering all key modalities, Bracco Imaging has a strong presence in key geographies: North America, Europe and Japan operating through the Joint Venture Bracco-Eisai Co. Ltd. The Company also operates in Brazil, South Korea, and China through the Joint Venture Bracco Sine Pharmaceutical Corp. Ltd.
Operational investments have been made in order to achieve top quality, compliant and sustainable eco-friendly production. Manufacturing activities are located in Italy, Switzerland, Japan, China, and Germany.
Bracco Imaging is an innovative Research and Development (R&D) structure with an efficient process oriented approach and a track record of innovation in the diagnostic imaging industry. R&D activities are managed in the three Research Centers located in Italy, Switzerland, and the USA.
To learn more about Bracco Imaging, visit www.braccoimaging.com.
Bracco Diagnostics Inc. Media Relations
SOURCE Bracco Diagnostics Inc.